The purpose of the Developmental Research Program is to promote the exploration of innovative ideas in translational research in lung cancer through the funding of pilot projects. Each year new pilot project applications are sought by the Developmental Research Committee, which is chaired by Dr. Bunn. Current committee members include Drs. Drabkin, Heasley, Franklin, Hirsch, Baron, and Keith. A request for application announcement is distributed to faculty at all consortium institutions of the University of Colorado Comprehensive Cancer Center (UCDHSC, CU-Boulder, Colorado State University, National Jewish Medical and Research Center, and The Children's Hospital). On average, 11 applications are received each year. The committee scores each application on its novelty, its likelihood of impacting the lung cancer burden through translational research, on its scientific merit, and on the qualifications of the investigators. The use of SPORE resources and the inclusion of collaborations with existing SPORE projects is also taken into consideration. Generally two applications are funded each year at a level of $50,000 each. Half of the support comes from SPORE funds and half comes from institutional funds. In some instances we have provided partial funding for worthy projects that could get started with more limited support. During the recent funding cycle we supported a total of 12 pilot projects. These projects and their outcomes are summarized in the following report. The success of our Developmental Research Program is demonstrated by the progression of a number of recent pilot projects into full SPORE projects. In this competitive renewal, Project 3 originated as a pilot project. As well, progress on the pilot projects of Dr. Heasley, of Dr. Meyer and of Drs. Solomon, Hansen and Duncan have been incorporated into the aims of Projects 2, 3 and 4, respectively. Pilot projects held by Drs. Nemenoff, Heasley, and Malkinson have led to current NCI R01s; the pilot project of Dr. Su has led to an NIH R21;and the pilot projects of Drs. Espinosa and Schiemann are incorporated into their NCI R01s. The research results from projects held by Drs. Franklin and Varella- Garcia were used to renew the NCI EDRN grant in 2005. As well, the Genetic Epidemiology Lung Cancer Consortium (GELCC) and the Lung Cancer Biomarkers &Chemoprevention Consortium (LCBCC) studies were also outcomes of SPORE pilot projects. Several other important lung cancer grants have been funded by other institutes and are described in this report.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
United States
Zip Code
Ghosh, Moumita; Miller, York E; Nakachi, Ichiro et al. (2018) Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:885-896
Farago, Anna F; Taylor, Martin S; Doebele, Robert C et al. (2018) Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol 2018:
He, Yayi; Liu, Sangtian; Mattei, Jane et al. (2018) The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther 12:981-986
Genova, Carlo; Socinski, Mark A; Hozak, Rebecca R et al. (2018) EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol 13:228-236
Merrick, Daniel T; Edwards, Michael G; Franklin, Wilbur A et al. (2018) Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res 78:4971-4983
Li, Howard Y; McSharry, Maria; Walker, Deandra et al. (2018) Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. Oncoimmunology 7:e1423182
Ravichandran, Kameswaran; Holditch, Sara; Brown, Carolyn N et al. (2018) IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol 314:F356-F366
Hilberg, Frank; Tontsch-Grunt, Ulrike; Baum, Anke et al. (2018) Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther 364:494-503
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
DeHart, David N; Fang, Diana; Heslop, Kareem et al. (2018) Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol 148:155-162

Showing the most recent 10 out of 435 publications